Yavuzs Silay
CEO
Labiopharma, LLC
Turkey
Biography
Dr. Silay is a member of American Academy of Neurology, chief editor of Journal of Developing Drugs, an editorial board member of Expert opinion on Emerging Drugs, a current ad-hoc reviewer at the NIH ( National Institute of Health) and NINDS, past speaker at DIA ( Drug Information Association) and member of DIA SIAC’s for Good Clinical Practice/Quality Assurance Special Interest Activity Community (GCP/QA SIAC), Clinical Trial Registry/Results Disclosure Working Group (CTR/RD Working Group), Natural Health Products. , MDS (Movement Disorder Society) , current chair of TABID (Turkish American Business Improvement Council) for Healthcare and Pharmaceutical Industry, charter and previous president of AMSA (American Medical Student Association) Turkey, previous president of SOCRA (Society of Clinical Research Associates) in New Jersey, board of directors member at the SoPE and founder of SoPE(Society of Physician Entrepreneurs) Turkey chapter.
Research Interest
Clinical Research, Medical Entrepreneurship, Strategic management consulting, Regulatory and Medical Consulting, Clinical Development, Medical Affairs, drug and medical device development, clinical trial design, Neurology, Oncology